Pathophysiology and therapies of CKD-associated secondary hyperparathyroidism
Clinical Kidney Journal · 13.03.2025 · 18 (Supplement_1) · i15-i26
DOI: 10.1093/ckj/sfae423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 13.03.2025. Verfasst von Sandro Mazzaferro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, Italy. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Vifor.
Abstract (Originalsprache)
Uremic secondary hyperparathyroidism (SHP) refers to the biochemical abnormalities that characterize CKD-MBD. However, historically parathyroid hormone (PTH) is identified as the key culprit hormone and the essential biomarker of secondary hyperparathyroidism. SHP represents the adaptive response to several mineral abnormalities that initiate and maintain increased PTH secretion through classical mineral derangements and more recently elucidated hormonal dysregulations. Among classic factors involved in the pathogenesis of SHP, phosphate, calcium, and calcitriol have a prominent role. The discovery of new pathogenetic factors involved in the development of SHP (and the eventual CKD-MBD) including fibroblast growth factor-23 (FGF23) and klotho provides new hypothesis and perspectives to our understanding of this complex metabolic disturbance. Recently more than serum phosphate a critical role in regulating FGF23 synthesis and the progression of CKD is ascribed to phosphate pool, reflected by production of glycerol-3-phosphate and the formation of excessive CPP-2. Finally, also skeletal resistance to PTH action, due to dysregulation of the Wnt–β-catenin system and intestinal dysbiosis, affecting the PTH actions on bone are causal factor of SHP. Identifying all the actors at play is mandatory to allow the most precise therapeutic prescription in the individual patient. This paper aims to review, in particular, the pathophysiology of SHP, which is essential to envisage the eventual therapeutic options for the associated MBD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translation and Precision Medicine, Sapienza University of Rome, Rome, Italy.
- Nephrology Unit, Department of Internal Medicine and Medical Specialties, Policlinico Umberto I Hospital, Rome, Italy.
- UOSD Dialysis, Department of Internal Medicine and Medical Specialties, Policlinico Umberto I Hospital, Rome, Italy.
- Department of Rheumatology, National Reference Center for Rare Bone Disease in Adults, Lariboisière Hospital, APHP. Nord, France.
- Inserm U1132, BIOSCAR, Paris, Université Paris Cité, Paris, France.
- NTT Hi-Tech Institute, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.
ORCID-Profile: Sandro Mazzaferro, Martine Cohen-Solal, Pablo Ureña Torres
Förderung
- CSL Vifor
Zitieren
APA
Mazzaferro, S., Tartaglione, L., Cohen-Solal, M., Hoang Tran, M., Pasquali, M., Rotondi, S., & Ureña Torres, P. (2025). Pathophysiology and therapies of CKD-associated secondary hyperparathyroidism. Clinical Kidney Journal, 18(Supplement_1), i15-i26. https://doi.org/10.1093/ckj/sfae423
Vancouver
Mazzaferro S, Tartaglione L, Cohen-Solal M, Hoang Tran M, Pasquali M, Rotondi S, et al. Pathophysiology and therapies of CKD-associated secondary hyperparathyroidism. Clinical Kidney Journal. 2025;18(Supplement_1):i15-i26. doi:10.1093/ckj/sfae423
BibTeX
@article{Mazzaferro2025,
author = {Mazzaferro, Sandro and Tartaglione, Lida and Cohen-Solal, Martine and Hoang Tran, Minh and Pasquali, Marzia and Rotondi, Silverio and Ureña Torres, Pablo},
title = {Pathophysiology and therapies of CKD-associated secondary hyperparathyroidism},
journal = {Clinical Kidney Journal},
year = {2025},
volume = {18},
number = {Supplement_1},
pages = {i15--i26},
doi = {10.1093/ckj/sfae423}
}
EUVIMED